About
Information about the European Ombudsman, the institution and its staff.
Strategy for the 2025-2029 mandate
Here you can find our Annual Report highlighting our work over 2025
Our annual management plans presenting how we plan to deliver our strategy for the coming year
Looking for a job with the European Ombudsman?
What we do
The Ombudsman investigates complaints about maladministration and looks into broader systemic issues with the EU institutions.
Inquiries into issues of public importance
Find out at a glance how it all works
Information and guidance on the right of public access to EU documents
Make a complaint
The Ombudsman can help people, businesses or organisations facing problems with the EU’s administration. This section explains under what circumstances and how.
Newsroom
Press releases, news, publications, multimedia, calendar and events, and media contacts.
Ombudswoman encourages Commission to fulfil AI Act objectives for energy consumption data
Ethics standards in the EU administration
Is EU law fit for purpose?
Watch this video and find out more about what the European Ombudsman does
You have a complaint against an EU institution or body?
HomeEMA's reply to EO's letter of 13 May 2014 on pu...
Contents
Letter - Date Monday | 02 June 2014
European Ombudsman reaction to EMA's 2 October 2014 adoption of its transparency policy concerning clinical trial data
Reply from the European Commission to the letter from the European Ombudsmanconcerning the transparency of clinical trials data
European Ombudsman reaction to EMA's 12 June 2014 statement issued after its Management Board meeting
Letter from the European Ombudsman to the European Commission concerning the transparency of clinical trials data
Ombudsman concerned about change of policy at Medicines Agency as regards clinical trial data transparency
EMA policy on publication of and access to clinical-trial data
Invitation to EO to attend a stakeholders consultation meeting on EMA's policy of publication of and access to clinical trial data
Finalisation of EMA policy on clinical trial data.2014.05-annex to invitation
Agenda-finalisation of EMA policy on clinical trial data-annex to invitation
Redaction principles DRAFT-annex to invitation
Terms of use DRAFT-annex to invitation